Completed PHASE1 INTERVENTIONAL NCT00000646

Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS

Sponsor: Hoechst Marion Roussel

Updated 6 times since 2017 Last updated: Oct 26, 2021 Completion: Mar 31, 1993

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on HIV Infections, this trial is completed. The trial is conducted by Hoechst Marion Roussel and has accumulated 6 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Dec 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Dec 2021 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoechst Marion Roussel
National Institute of Allergy and Infectious Diseases (NIAID)

Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States
• Cleveland, United States